Literature DB >> 22514408

Comparative activity of cefepime with several antimicrobials against aerobic Gram-negative and Gram-positive organisms isolated from patients across Canada in 1993.

D E Low1.   

Abstract

To compare the activity of cefepime, a fourth-generation cephalosporin, with several available antimicrobials, in vitro susceptibility studies were carried out on bacteria commonly associated with various infections, including sepsis. Ten tertiary care hospital laboratories in six provinces provided 1276 clinically relevant isolates of aerobic Gram-negative bacilli and Gram-positive cocci during 1993. When the activity of each of the antimicrobials was determined against all isolates submitted, cefepime, piperacillin/tazobactam, imipenem and ciprofloxacin all had minimal inhibitory concentrations for 90% of the organisms (mic(90)) two or more dilutions below the mic resistant category. Gentamicin's mic(90) against all organisms tested was one dilution below the mic resistant category. The mic(90)s of the third-generation cephalosporins, piperacillin and ticarcillin/clavulanate, for Enterobacter species fell in the resistant category. This is presumably due to constitutive high level chromosomal cephalosporinase production. The mic(90)s of cefepime for Enterobacter species was three or more dilutions below the mic resistant category. The mic(90)s of all antimcrobials against Staphylococcus aureus, with the exception of ceftazidime and piperacillin, had mic(90) categories two or more dilutions below the resistant category. The activity of cefepime, piperacillin/tazobactam, imipenem, ciprofloxacin and gentamicin make them excellent candidates for the empirical therapy of serious infections due to aerobic Gram-negative bacilli and S aureus.

Entities:  

Keywords:  Antimicrobial agents; Antimicrobial resistance; Cefepime; Surveillance

Year:  1995        PMID: 22514408      PMCID: PMC3327936          DOI: 10.1155/1995/458762

Source DB:  PubMed          Journal:  Can J Infect Dis        ISSN: 1180-2332


  22 in total

Review 1.  Classification of beta-lactamases: groups 1, 2a, 2b, and 2b'.

Authors:  K Bush
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

2.  Comparative in vitro activity of cefpirome and cefepime, two new cephalosporins.

Authors:  A King; C Boothman; I Phillips
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-09       Impact factor: 3.267

3.  Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System.

Authors:  S N Banerjee; T G Emori; D H Culver; R P Gaynes; W R Jarvis; T Horan; J R Edwards; J Tolson; T Henderson; W J Martone
Journal:  Am J Med       Date:  1991-09-16       Impact factor: 4.965

4.  HR 810 and BMY-28142, two new cephalosporins with broad-spectrum activity: an in-vitro comparison with other beta-lactam antibiotics.

Authors:  A M Clarke; S J Zemcov; J M Wright
Journal:  J Antimicrob Chemother       Date:  1985-03       Impact factor: 5.790

5.  In vitro activity of BMY-28142 in comparison with those of other beta-lactam antimicrobial agents.

Authors:  A Tsuji; A Maniatis; M A Bertram; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

6.  In-vitro activity of cefepime and other antimicrobials: survey of European isolates.

Authors:  C Thornsberry; S D Brown; Y C Yee; S K Bouchillon; J K Marler; T Rich
Journal:  J Antimicrob Chemother       Date:  1993-11       Impact factor: 5.790

7.  Antibiotic susceptibility profiles of 941 gram-negative bacteria isolated from septicemic patients throughout Canada. The Canadian Study Group.

Authors:  S Chamberland; J L'Ecuyer; C Lessard; M Bernier; P Provencher; M G Bergeron
Journal:  Clin Infect Dis       Date:  1992-10       Impact factor: 9.079

8.  The activity of BMY 28142 a new broad spectrum beta-lactamase stable cephalosporin.

Authors:  H C Neu; N X Chin; K Jules; P Labthavikul
Journal:  J Antimicrob Chemother       Date:  1986-04       Impact factor: 5.790

9.  Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum beta-lactam antibiotics.

Authors:  R E Kessler; M Bies; R E Buck; D R Chisholm; T A Pursiano; Y H Tsai; M Misiek; K E Price; F Leitner
Journal:  Antimicrob Agents Chemother       Date:  1985-02       Impact factor: 5.191

Review 10.  Clinical implications of positive blood cultures.

Authors:  C S Bryan
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

View more
  1 in total

1.  In vitro activity of cefepime against multidrug-resistant Gram-negative bacilli, viridans group streptococci and Streptococcus pneumoniae from a cross-Canada surveillance study.

Authors:  D E Low; J de Azavedo; R Davidson
Journal:  Can J Infect Dis       Date:  1999-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.